Curis shares surge 17.70% intraday on positive emavusertib data presentation at SNO meeting.

Curis surged 17.70% intraday after announcing the presentation of promising preclinical and clinical data on emavusertib, an IRAK4 inhibitor, at the 30th SNO Annual Meeting in November 2025. The news highlighted the drug’s potential in treating CNS lymphomas, particularly in combination with BTK inhibitors, and emphasized collaborative research efforts with leading institutions. These developments underscored Curis’s progress in precision oncology, aligning with the stock’s sharp intraday gains. The second news item, referencing generic updates on Curis Lifesciences Ltd. without specific details, was deemed unrelated to the price movement.